<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="6019">
  <stage>Registered</stage>
  <submitdate>13/01/2015</submitdate>
  <approvaldate>13/01/2015</approvaldate>
  <nctid>NCT02341560</nctid>
  <trial_identification>
    <studytitle>Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 in Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)</studytitle>
    <scientifictitle>A Phase 2/3, Randomized, Double-Masked, Sham-Controlled Trial of QPI-1007 Delivered By Single or Multi-Dose Intravitreal Injection(s) to Subjects With Acute Nonarteritic Anterior Ischemic Optic Neuropathy (NAION)</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>QRK207</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Nonarteritic Anterior Ischemic Optic Neuropathy</healthcondition>
    <conditioncode>
      <conditioncode1>Cardiovascular </conditioncode1>
      <conditioncode2>Diseases of the vasculature and circulation including the lymphatic system</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Eye</conditioncode1>
      <conditioncode2>Diseases / disorders of the eye</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Neurological</conditioncode1>
      <conditioncode2>Other neurological disorders</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - QPI-1007 Injection - single low dose
Treatment: drugs - QPI-1007 Injection - single high dose
Treatment: drugs - QPI-1007 Injection - multiple low dose
Treatment: drugs - QPI-1007 Injection - multiple high dose
Other interventions - Sham Injection Procedure

Active Comparator: Cohort 1 - QPI-1007 Injection - single low dose

Active Comparator: Cohort 2 - QPI-1007 Injection - single high dose

Active Comparator: Cohort 3 - QPI-1007 Injection - multiple low dose

Active Comparator: Cohort 4 - QPI-1007 Injection - multiple high dose

Sham Comparator: Cohort 5 - Sham injection procedure


Treatment: drugs: QPI-1007 Injection - single low dose
QPI-1007 Injection, single low dose

Treatment: drugs: QPI-1007 Injection - single high dose
QPI-1007 Injection, single high dose

Treatment: drugs: QPI-1007 Injection - multiple low dose
QPI-1007 Injection, multiple low dose

Treatment: drugs: QPI-1007 Injection - multiple high dose
QPI-1007 Injection, multiple high low dose

Other interventions: Sham Injection Procedure
Sham Procedure

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Effect of QPI-1007 as assessed by Best Corrected Visual Acuity (BCVA)</outcome>
      <timepoint>Baseline through Month 12</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Safety and tolerability of QPI-1007 as assessed by adverse events (AE), laboratory evaluations, ECGs, ophthalmic evaluations, slit lamp anterior/posterior examinations, intraocular pressure measurements, presence/absence of vitreous inflammation</outcome>
      <timepoint>Baseline through Month 12</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change in BCVA score, as measured by ETDRS visual acuity protocol in the study eye</outcome>
      <timepoint>Day 1 through Month 12</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Mean change of Visual Fields, as assessed by Humphrey standard automated perimetry using the SITA standard 24-2 testing protocol in the study eye</outcome>
      <timepoint>Day 1 through Month 12</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>Key 

          -  Positive diagnosis of first episode of NAION in the study eye with symptom onset
             within 14 days prior to planned study drug administration/sham procedure

          -  Best corrected visual acuity score in the study eye is better than or equal to 15
             letter score, measured using the ETDRS visual acuity protocol at Day 1 prior to study
             drug administration/sham procedure.

          -  Clear ocular media and able to undergo adequate pupil dilation to allow a good fundus
             examination

        Key</inclusivecriteria>
    <inclusiveminage>50</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>80</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Present use or history of any treatment for the current episode of NAION, including
             systemic steroids, brimonidine, or traditional Chinese herbal medicine

          -  Prior episode of NAION in the study eye only

          -  Present use of drugs known to cause optic nerve or retinal toxicity at Day
             1/Randomization, such as: chloroquine or hydroxychloroquine, ethambutol, Vigabatrin.
             Subjects who need to be prescribed any of these drugs during the course of the study
             will be discontinued from the trial.

          -  Any medical condition, concomitant therapy, or previous incisional or laser surgery
             that, in the opinion of the Investigator, would preclude IVT injection in the study
             eye only

          -  Clinical evidence of temporal arteritis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2/Phase 3</phase>
    <anticipatedstartdate />
    <actualstartdate>1/10/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize>530</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <anticipatedlastvisitdate>1/07/2019</anticipatedlastvisitdate>
    <actuallastvisitdate />
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Sydney Eye Hospital/Save Sight Institute - Sydney</hospital>
    <hospital>Westmead Hospital - Sydney</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Vision South Australia - Kent Town</hospital>
    <hospital>The Royal Victorian Eye and Ear Hospital - Fitzroy</hospital>
    <hospital>Royal Perth Hospital - Perth</hospital>
    <postcode>2000 - Sydney</postcode>
    <postcode>2145 - Sydney</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>5267 - Kent Town</postcode>
    <postcode>3002 - Fitzroy</postcode>
    <postcode>6000 - Perth</postcode>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Arkansas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>California</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Colorado</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Connecticut</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Florida</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Illinois</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Kentucky</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Maryland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Massachusetts</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Michigan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Minnesota</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Missouri</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Nebraska</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New Jersey</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>New York</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>North Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Ohio</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Oklahoma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Pennsylvania</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>South Carolina</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Texas</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Utah</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Virginia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>United States</country>
      <state>Washington</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hunan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Sichuan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Beijing</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Rheinland-Pfalz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Aachen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Dresden</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Karlsruhe</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>MÃ¼nster</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Regensburg</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Germany</country>
      <state>Tubingen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Andhra Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Assam</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Karnataka,</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Maharashtra</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Orissa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tami Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Tamil Nadu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Uttar Pradesh</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>New Delhi</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>India</country>
      <state>Wardha</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>HaMerkaz</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Yerushalayim</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Beer-Sheva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Haifa</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Petach-Tikva</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Rehovot</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Aviv</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Israel</country>
      <state>Tel-Hashomer</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Bologna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Firenze</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Milano</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Parma</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Italy</country>
      <state>Torino</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Singapore</country>
      <state>Singapore</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Quark Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will determine the effect of QPI-1007 on visual function in subjects with
      recent-onset NAION and assess the safety and tolerability of intravitreal injections of
      QPI-1007 in this population. This study will also evaluate the structural changes in the
      retina following administration of QPI-1007.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02341560</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Sharon Klier, M.D.</name>
      <address>Quark Pharmaceuticals</address>
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name>Robert Shopbell</name>
      <address />
      <phone>510.402.4005</phone>
      <fax />
      <email>rshopbell@quarkpharma.com</email>
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>